Portal de Periódicos da CAPES

The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

2021; BioMed Central; Volume: 21; Issue: 1 Linguagem: Inglês

10.1186/s12935-021-02382-0

1475-2867

Gabriela Fernandes, Natália Martins, José Carlos Machado, José Luís Costa, Venceslau Hespanhol,

Genetic factors in colorectal cancer

Liquid biopsy (LB) has boosted a remarkable change in the management of cancer patients by contributing to tumour genomic profiling. Plasma circulating cell-free tumour DNA (ctDNA) is the most widely searched tumour-related element for clinical application. Specifically, for patients with lung cancer, LB has revealed valuable to detect the diversity of targetable genomic alterations and to detect and monitor the emergence of resistance mechanisms. Furthermore, its non-invasive nature helps to overcome the difficulty in obtaining tissue samples, offering a comprehensive view about tumour diversity. However, the use of the LB to support diagnostic and therapeutic decisions still needs further clarification. In this sense, this review aims to provide a critical view of the clinical importance of plasma ctDNA analysis, the most widely applied LB, and its limitations while anticipating concepts that will intersect the present and future of LB in non-small cell lung cancer patients.